pharma · Rectal Cancer
Changhai Hospital drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Portfolio lens on 2 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Changhai Hospital drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
US regulatory status: approved. Molecular target: Vascular endothelial growth factor A, long form.
Antineoplastic and immunomodulating agents (L01) compound in Changhai Hospital's portfolio. Molecular target: Programmed cell death protein 1.